| Can Bristol-Myers Squibb Heal Your Portfolio? Bud Labitan submitsBristol-Myers Squibb Company (BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical products on a global basis. The Company’s products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States, Puerto Rico and in eight foreign countries. In September 2009, BMS acquired Medarex, Inc., and in December 2009, it divested the Mead Johnson Nutrition Company (MJN).Last Price: $23.5552 Week High: $27.0752 Week Low: $19.12 Does BMY make for an intelligent investment or intelligent speculation today?Complete Story » seekingalpha.com |
Is Pharmaceutical Innovation Running Dry? Karl Smith submits: By Adam OzimekThis comes from F.M. Scherer’s paper on pharmaceutical innovation written for the Handbook of the Economics of Technical Change: Complete Story » seekingalpha.com |
AVANIR Pharmaceuticals F3Q10 (Qtr End 06/30/10) Earnings Call Transcript AVANIR Pharmaceuticals (AVNR)F3Q10 (Qtr End 06/30/10) Earnings CallComplete Story » seekingalpha.com |
Workout Gear That Goes Easy on Joints More people are saying good-bye to the machine-laden gym and looking for equipment designed to give low-impact workouts and then tuck neatly in a closet, suitcase or an SUV. online.wsj.com |
Levetown & Jenkins, LLP Announces an Investigation of the Acquisition of Clarient, Inc. by GE Healthcare, a unit of General Electric Company [Business Wire] - Levetown & Jenkins, LLP is conducting an investigation into alleged breaches of fiduciary duties and violations of state law by Clarient, Inc. and its Board of Directors in conjunction with the proposed buyout and acquisition of Clarient by GE Healthcare, a unit of General Electric Company . us.rd.yahoo.com |